Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 79,410 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions: busulfan, etoposide, intensity-modulated radiation therapy, allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, tomotherapy; Drug · Radiation · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 6 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Duarte, California

Conditions: Bone Regeneration
Interventions: Membrane Jason MB GmbH Non-cross-linked (NCL), Membrane BioMend Extend Glutaraldehyde cross-linked, Membrane OSSIX Agile Ribose cross-linked (RCL); Device
Lead sponsor: Andrea Ravida; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypothyroidism
Interventions: Armour Thyroid, Levothyroxine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 134
States / cities: Birmingham, Alabama • Bonita, California • Burbank, California + 110 more

Conditions: Hypertriglyceridemia
Interventions: Diazoxide choline, Placebo; Drug
Lead sponsor: Essentialis, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Miami Gardens, Florida + 8 more

Conditions: Contact Lens Solution
Interventions: Opti-Free contact lens solution, ReNu Multiplus contact lens solution, Clear Care contact lens solution; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Virginia Beach, Virginia

Conditions: Depression, Postpartum, Depression
Interventions: The Postpartum Prevention Program (PPP), Enhanced care as usual (ECU); Behavioral
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Providence, Rhode Island • Woonsocket, Rhode Island

Conditions: Intraosseous Vascular Access, Vascular Access
Interventions: Intraosseous Vascular Access; Device
Lead sponsor: Vidacare Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Spring Branch, Texas

Conditions: Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
Interventions: Insulin glargine, insulin NPH; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Opioid-use Disorder
Interventions: PCP brief advice, Video doctor, Telephone health coaching, Nurse Care Manager (NCM) intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: Adjuvant Patient Navigation for Tobacco Treatment; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Prevention
Interventions: SEPA III; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Normal Renal Function, Impaired Renal Function
Interventions: LEE011; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pain, Anxiety, Nausea
Interventions: Midazolam, Ibuprofen, Placebo-Cherry syrup, Lidocaine; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cancer-related Cognitive Dysfunction, Primary Brain Neoplasm
Interventions: Aerobic Exercise, Behavioral Intervention, Follow-Up, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Resistance Training; Other · Behavioral · Procedure
Lead sponsor: Emory University; Other
Eligibility: 15 Years to 39 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • Houston, Texas

Conditions: Prostate Cancer
Interventions: SpaceOAR System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Phoenix, Arizona • Campbell, California • Sacramento, California + 16 more

Conditions: Covid19
Interventions: Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday; Behavioral
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Cirrhosis, Hepatic Encephalopathy
Interventions: HPN-100, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 28
States / cities: Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 21 more

Conditions: Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)
Interventions: Bruton's tyrosine kinase inhibitor, B-Cell Lymphoma 2 Protein Inhibitor; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Obesity
Interventions: 2 no calorie beverages per day, 2 water beverages per day; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 65 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: Non Alcoholic Steatohepatitis
Interventions: Elafibranor 80mg, Elafibranor 120mg; Drug
Lead sponsor: Genfit; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: San Diego, California • New York, New York

Conditions: Smith-Lemli-Opitz Syndrome
Interventions: Simvastatin Susp., OraPlus; Drug
Lead sponsor: Forbes Porter, M.D.; NIH
Eligibility: 4 Years to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: EWINGS SARCOMA
Interventions: Rabbit anti-thymocyte globulin, Busulfan, Melphalan, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: University of Louisville; Other
Eligibility: Up to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Smoking, Schizophrenia
Interventions: Physostigmine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Periprosthetic Joint Infection
Interventions: Single Debridement, Antibiotics and Implant Retention, Planned Double Debridement, Antibiotics and Implant Retention; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Search by objective public record fields.

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Comparative Study of Three Collagen Membranes: 1 Non-cross-linked and 2 Cross-linked

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Diazoxide Choline in Hypertriglyceridemia

Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina

Depression Prevention for Pregnant Women on Public Assistance

Follow-Up Study Validating a Blended Technique to Identify the Proximal Humerus Intraosseous Vascular Access Site

RCT Glargine vs NPH for Treatment of DM in Pregnancy

Subthreshold Opioid Use Disorder Prevention (STOP) Trial

Feasibility, Acceptability and Fidelity of Integrating a Navigation Intervention Into Tobacco Treatment Program

SEPA III: The Effectiveness Trial

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

Evaluation of Oral Midazolam in First-trimester Surgical Abortions

Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors

SpaceOAR System Pivotal Study

The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

The Role of No-Calorie Beverages Within a Weight Loss Program

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

Simvastatin Therapy in Smith-Lemli-Opitz Syndrome

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors

Treatment of Acute Periprosthetic Joint Infection Comparing Single and Planned Double-Debridement Antibiotics and Implant Retention Followed by Chronic Antibiotic Suppression